NEW ADDRESS (as of 25.07.2022) IELSG Headquarters Foundation for the Institute of Oncology Research (IOR) Via Vincenzo Vela, 6 CH-6500 Bellinzona Phone + 41 58 666 73 21 ielsg@ior.usi.ch
IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
Reference Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386. Link Author(s) Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, […]
Lancet Haematol 2021; 8: e110-21. Authors: Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C,
Re F, Fanni A, Singh V, Bromberg JCE, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E,
Cwynarski K, for the International Extranodal Lymphoma Study Group (IELSG)
Extranodal NHLs can arise from a variety of anatomical districts. Participation is open to worldwide institutions.
For further information about the clinical trials, please contact us.
...
The IELSG is as a branch of the Foundation for the Institute of Oncology Research and develops non-profit and independent scientific research projects to improve the knowledge and the treatm...
Since 1998, an Annual Meeting of the IELSG investigators is held.
The meeting aims to bring together physicians and
scientists from all over the world to present and discuss the ongoi...